Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HS-20124
- Development stage
- Phase 1
- Lead developer
- Hansoh BioMedical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
HS-20124 is a novel antibody-drug conjugate (ADC) of the DAR-8 type that targets Cadherin 6 (CDH6). It was initially developed by Changzhou Humon Pharmaceutical and is currently being developed by Hansoh BioMedical R&D Company. The drug is designed to inhibit tumor cell growth in cancers expressing CDH6, as demonstrated in preclinical studies both in vitro and in vivo. Its mechanism involves targeted delivery of cytotoxic agents to tumor cells via binding to the CDH6 antigen, though the precise payload and linker details are not specified. HS-20124 has entered Phase 1 clinical trials for patients with advanced solid tumors, where its safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity are being evaluated[1][2][3][6].
02
Targets
CDH6 (Cadherin-6)
Beyond the preview
Go deeper on HS-20124.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HS-20124.